Japan’s Kyowa Kirin has reached an agreement to buy Orchard Therapeutics of the UK in a deal valued at up to $478 million, ahead of an FDA decision on the biotech’s lead g
German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe.<
Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson's disease candidate KW-6356, a drug in the adenosine A2A
NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin's Poteligeo for two rare blood cancers, ending the threat of a north-south divide in access to the drug in the
Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion of the label of Ultomiris, one of the main assets behind the
A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin's Poteligeo for two rare blood cancers, a few weeks after the drug w
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year